4results about How to "Suitable for clinical application" patented technology

This invention belongs to the field of biomedicine and regenerative medicine technology. It discloses a chimeric polypeptide, related biomaterials, and their application in inducing cardiomyocytes. The chimeric polypeptide is obtained through family homologous domain substitution and is selected from the following groups: (1) a MEF2 chimeric polypeptide with MEF2C protein as the backbone, wherein the N-terminal and C-terminal transcriptional activation domains are replaced by homologous regions of MEF2B and MEF2D, respectively; (2) a GATA chimeric polypeptide with GATA4 protein as the backbone, wherein the N-terminal transcriptional activation domain is replaced by homologous regions of GATA1 and GATA6. This invention also provides the nucleic acid encoding the polypeptide, the construct, and a method for efficiently inducing fibroblast reprogramming into cardiomyocytes under in vitro conditions. When the chimeric polypeptide of this invention is used alone or in combination, the induced cells exhibit calcium ion oscillations earlier and have higher maturity.

The invention is applicable to the field of genetic engineering, and provides a mycobacterium tuberculosis 32C-PPE18-LS protein nanoparticle, a preparation method and application thereof, the mycobacterium tuberculosis 32C-PPE18-LS protein nanoparticle is formed by sequence fusion of a C terminal of a mycobacterium tuberculosis MTB32A protein, a PPE18 protein and an LS protein, and the amino acid sequence of the mycobacterium tuberculosis 32C-PPE18-LS protein nanoparticle is shown in a sequence table SEQ ID NO: 2. According to the mycobacterium tuberculosis 32C-PPE18-LS protein nanoparticles provided by the invention, multi-fragment immunogenic protein fusion is adopted, a synergistic immune effect can be induced, and the immunostimulation ability of an antigen is remarkably enhanced. Moreover, the 32C-PPE18-LS protein nanoparticles are non-toxic and free of pathogenicity, so that the vaccine can be ensured to have good biological safety, and the 32C-PPE18-LS protein nanoparticles are suitable for clinical application.

The invention is applicable to the field of gene engineering, and provides a mycobacterium tuberculosis RpfB-LS protein nanoparticle, a preparation method and application thereof, the mycobacterium tuberculosis RpfB-LS protein nanoparticle is formed by sequence fusion of mycobacterium tuberculosis RpfB protein and LS protein, and the amino acid sequence of the mycobacterium tuberculosis RpfB-LS protein nanoparticle is shown in a sequence table SEQ ID NO: 2. The RpfB-LS protein nanoparticles provided by the invention are non-toxic and free of pathogenicity, can ensure that vaccines have good biological safety, and are suitable for clinical application. Animal experiments show that after a mouse is immunized by the RpfB-LS protein nanoparticle, strong humoral immunity (antibody generation) and cellular immunity (T cell response) can be stimulated at the same time, and it is proved that the recombinant RpfB-LS protein nanoparticle vaccine can effectively induce specific immune protection.

This invention discloses a kit for detecting HPV integration sites, belonging to the field of genetic engineering. Using this invention, targeted sequencing of partially unknown sequences can be performed at very low sequencing throughput (approximately 400K-600K) to obtain sufficient data (approximately 50X coverage depth) to yield reliable results. It can detect HPV integration in samples including, but not limited to, cervical cancer samples. Another objective of this invention is to verify the integration status of primer-corresponding regions using methods such as hybridization, quantitative fluorescence sequencing, or first-generation sequencing, employing single or partial primers provided by this invention. The presence of HPV integration strongly suggests that the patient's condition is CIN and cervical cancer. This invention provides more data support for the clinical research and diagnosis of cervical cancer from the perspective of HPV integration.